Davis Polk advised Credit Suisse Securities (USA) LLC as representative of the several underwriters of a $46 million SEC-registered follow-on offering of 7,076,922 shares of common stock of XenoPort, Inc. Xenoport’s common stock is traded on the Nasdaq Global Select Market under the symbol “XNPT.”

Based in Santa Clara, California, XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant (gabapentin enacarbil) Extended-Release Tablets is approved in the United States for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia in adults. Regnite (gabapentin enacarbil) Extended-Release Tablets is approved for the treatment of RLS in Japan. XenoPort’s pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson’s disease and relapsing-remitting multiple sclerosis.

The Davis Polk corporate team included partner Bruce K. Dallas, associate Sara Chang and law clerk Patrick Ekeruo. Partner Rachel D. Kleinberg and associate Omer Harel provided tax advice. Associates Emma Maconick and Bruce Rose-Innes provided intellectual property advice. Kimberly Kakade was the legal assistant on the transaction. Members of the Davis Polk team are based in the Menlo Park and New York offices.